In the pre-clinical study, vaccinated animals lost less weight and had less virus in their lungs and other organs than unvaccinated animals. (https://bit.ly/3gVS8ey) The company began early-stage human trials in the United States and Belgium in July, after details of a study in monkeys showed its best-performing vaccine candidate offered strong protection in a single dose. Depending on data from the early-stage trial, J&J plans to begin phase 3 testing in the second half of September. In the pre-clinical study reported on Thursday, Syrian golden hamsters, which are more susceptible to diseases than monkeys, were first vaccinated and then exposed to the novel coronavirus after four weeks. The researchers found low levels of antibodies that can neutralize the virus were tied to high levels of weight loss and viral replication in the lungs. (Reporting by Manas Mishra in Bengaluru; Editing by Shounak Dasgupta) Please note you must be a Maverick Insider to comment. Sign up here or sign in if you are already an Insider. Everybody has an opinion but not everyone has the knowledge and the experience to contribute meaningfully to a discussion. Thatâ€™s what we want from our members. Help us learn with your expertise and insights on articles that we publish. We encourage different, respectful viewpoints to further our understanding of the world. View our comments policy here. No Comments, yet